Ameet Mallik taps fel­low No­var­tis alum to lead busi­ness de­vel­op­ment at ADC Ther­a­peu­tics

Just one month in­to his CEO tenure at ADC Ther­a­peu­tics, Ameet Mallik is bring­ing in new peo­ple to as­sem­ble his top team.

David Gilman, a sea­soned bio­phar­ma con­sul­tant who held a brief stint scout­ing deals for No­var­tis’ on­col­o­gy group, is join­ing the Swiss biotech as chief busi­ness and strat­e­gy of­fi­cer.

A vet­er­an of No­var­tis him­self, Mallik jumped to ADC last month af­ter his first CEO ex­pe­ri­ence at Rafael Hold­ings im­plod­ed, re­plac­ing Chris Mar­tin, the long-time chief who’d been in­volved with the com­pa­ny since its for­ma­tion in 2011 and over­saw a slate of fi­nanc­ings, deals, an IPO and an FDA ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER